Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $584.18 Consensus Price Target from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. Eleven equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $584.1818.

MEDP has been the topic of several recent analyst reports. Robert W. Baird boosted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 17,610 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the sale, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,231 shares of company stock worth $30,187,908 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. Johnson Financial Group Inc. purchased a new stake in shares of Medpace in the second quarter worth approximately $27,000. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace in the fourth quarter worth approximately $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter worth approximately $30,000. Finally, Allied Private Wealth LLC purchased a new stake in Medpace in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 1.4%

MEDP opened at $596.98 on Monday. The stock’s 50 day simple moving average is $531.28 and its 200-day simple moving average is $491.78. The stock has a market cap of $16.66 billion, a PE ratio of 34.99, a P/E/G ratio of 2.70 and a beta of 1.15. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the business earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace will post 17.54 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.